Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. Under the leadership of ...
Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...
This biotech company has a track record of commercializing products and delivering growth. It also has strengths in research and development. When you think of biotech companies, you may think of ...
Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It’s a great idea to select tomorrow's potential winners and hold on as their stories unfold. If you're ...
Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks. Novartis is shelling out $100 ...
Vision loss remains one of the leading causes of disability worldwide, with millions affected by inherited retinal diseases, age-related macular degeneration, and diabetic eye disease. While existing ...
Known for its architecture, coasts and vibrant culture, Barcelona is a premier European life sciences hub, ranking sixth in scientific output, according to the Barcelona City Council, and contributes ...
EyePoint (EYPT), Janux (JANX), Kyverna (KYTX), and Viking (VKTX) have analyst targets implying 179% to 384% upside. Janux and Kyverna hold the highest upside projections at 384% and 308% respectively, ...
‘My scientific career is essentially over.’ A brain drain imperils Massachusetts’ biomedical future.
A prominent cancer scientist is uprooting his Harvard University lab of two decades and moving it to Texas. A laid-off expert on aging abandoned academia for a more secure municipal research job in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results